"In a comment on the study, Jan Dorr of the NeuroCure Clinical Research Center in Berlin, described the results as "impressive".But, "will this study change our approach to treatment of multiple sclerosis? "Since this is aggressive treatment, the potential benefits should be weighted against the risk of serious complications associated with aHSCT. Probably not in the short term, mainly because the mortality rate will still be considered unacceptably high," he wrote. "The sample size of 24 patients is very small," said study co-author Mark Freedman of the Ottawa Hospital Research Institute, urging caution in interpreting the findings.Larger clinical trials must confirm the results, he said. "The initial 24 MRI scans revealed 93 brain lesions, and after the treatment only one of the 327 scans showed a new lesion," the team said.After three years, six patients were able to reduce or stop their disability insurance, and return to work or school.

Source: Economic Times June 11, 2016 02:44 UTC